Cresco successfully advises on €9 million Series A investment in Azalea Vision

Cresco is proud to have acted as legal counsel in the first closing of Azalea Vision’s €15 million Series A funding round. The round saw participation from several historical investors, SPRIM Global Investments, Afrimobility, and an undisclosed strategic investor.

Azalea Vision, a spin-off from imec and Ghent University, is developing ALMA – a groundbreaking smart contact lens platform that integrates liquid-crystal technology, microelectronics, and biosensing to offer real-time, non-invasive solutions for patients with vision disorders such as keratoconus, presbyopia, and photophobia.

The Series A funding will support the execution of Azalea Vision’s First-in-human (FIH) pilot clinical trial, a key milestone in establishing the safety and performance of its medically intelligent ocular technology platform.

Cresco is pleased to have supported Azalea Vision not only on the corporate side of this transaction, but also in its day-to-day operations—helping structure its commercial agreements, safeguard its intellectual property, and accelerate the development and deployment of its innovative technology.

We look forward to continuing our collaboration and supporting Azalea Vision as it reshapes the future of connected vision care.

Congratulations to Enrique Vega, Andrés Vásquez Quintero and the whole Azalea Vision team!

The Cresco deal team was led by Olivier Van Raemdonck and further consisted of Elske Bleeker and Charles Groffils.

For more information, please visit De Tijd.